- Home
- NBIX vs REG Comparison
NBIX vs REG Comparison
Compare NBIX & REG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- REG
- Stock Information
- Founded
- NBIX 1992
- REG 1963
- Country
- NBIX United States
- REG United States
- Employees
- NBIX N/A
- REG N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- REG Real Estate Investment Trusts
- Sector
- NBIX Health Care
- REG Real Estate
- Exchange
- NBIX Nasdaq
- REG Nasdaq
- Market Cap
- NBIX 11.6B
- REG 13.3B
- IPO Year
- NBIX 1996
- REG 1993
- Fundamental
- Price
- NBIX $120.69
- REG $73.33
- Analyst Decision
- NBIX Buy
- REG Buy
- Analyst Count
- NBIX 21
- REG 13
- Target Price
- NBIX $168.35
- REG $77.62
- AVG Volume (30 Days)
- NBIX 1.6M
- REG 974.3K
- Earning Date
- NBIX 02-06-2025
- REG 02-06-2025
- Dividend Yield
- NBIX N/A
- REG 3.85%
- EPS Growth
- NBIX 33.20
- REG 3.43
- EPS
- NBIX 3.29
- REG 2.11
- Revenue
- NBIX $2,355,300,000.00
- REG $1,503,291,000.00
- Revenue This Year
- NBIX $16.29
- REG N/A
- Revenue Next Year
- NBIX $16.90
- REG $4.57
- P/E Ratio
- NBIX $36.68
- REG $34.75
- Revenue Growth
- NBIX 24.81
- REG 9.81
- 52 Week Low
- NBIX $110.95
- REG $56.51
- 52 Week High
- NBIX $157.98
- REG $76.53
- Technical
- Relative Strength Index (RSI)
- NBIX 35.76
- REG 52.42
- Support Level
- NBIX $113.00
- REG $71.90
- Resistance Level
- NBIX $118.61
- REG $74.17
- Average True Range (ATR)
- NBIX 4.28
- REG 1.36
- MACD
- NBIX -2.22
- REG 0.03
- Stochastic Oscillator
- NBIX 18.81
- REG 57.60
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
About REG Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.